@article{3045816,
    title = "TREATMENT OF POLYCYSTIC OVARIAN DISEASE DURING ADOLESCENCE WITH
ETHINYLESTRADIOL CYPROTERONE-ACETATE VERSUS A D-TR-6-LHRH ANALOG",
    author = "CREATSAS, G and HASSAN, E and DELIGEOROGLOU, E and TOLIS, G and and ARAVANTINOS, D",
    journal = "International Journal of Gynecology and Obstetrics",
    year = "1993",
    volume = "42",
    number = "2",
    pages = "147-153",
    publisher = "ELSEVIER SCI IRELAND LTD",
    issn = "0020-7292",
    doi = "10.1016/0020-7292(93)90629-B",
    keywords = "POLYCYSTIC OVARIAN DISEASE; ADOLESCENCE; LHRH ANALOG; CYPROTERONE
ACETATE; HIRSUTISM; OLIGOMENORRHEA",
    abstract = "OBJECTIVE: This study was undertaken to compare the clinical and
endocrinological results of two kinds of treatment on adolescents with
polycystic ovarian disease (PCOD). METHOD: Forty-five adolescents with
PCOD were randomly allocated into two groups, treated either with
ethinylestradiol (EE)/cyproterone acetate (group A) or the GnRH analog
D-Tr-6-LHRH (group B). RESULT: No significant changes were detected on
the body mass index and waist-hip circumference. A significant
improvement of hirsutism was noticed in both groups of patients. A
normal menstrual period was recorded in group A adolescents while all
group B patients became amenorrheic. A favorable decrease of ovarian
volume was detected in both groups. LH/FSH ratio and
DELTA4-androstenedione serum levels were found significantly reduced in
both groups in comparison to pre-treatment levels. The comparison
between the two groups, after 6 months, showed significantly lower
values of LH/FSH ratio in group B cases. CONCLUSION: Both forms of
treatment are safe and effective to a various degree for the management
of PCOD adolescents."
}